GNMA 3: How can early access schemes support accelerated patient access in Europe?

Bringing a new treatment to market requires marketing authorisation (MA) and successful pricing and reimbursement negotiations. Early access programmes (EAPs) and schemes allows access to medicines for rare or severe diseases. These programmes can have a significantly positive impact for patients, where patients can access orphan drugs which they may not be able to otherwise.
This guidance note focusses on early access schemes in Europe, discussing how to use these regulatory opportunities, the types of schemes available, stakeholder engagement opportunities, and the likelihood of achieving an early access recommendation.

This content is restricted to members. To view this content please register or login below to view this content.

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free